PDI
MD Anderson, Summit Therapeutics to Jointly Study Ivonescimab
The partners inked a five-year deal to study the PD-1/VEGF bispecific antibody across multiple tumor types, including in biomarker-defined indications.
Junshi Biosciences Eyeing Toripalimab Regulatory Submission in Triple-Negative Breast Cancer
The Shanghai-based firm plans to hold regulatory discussions following a positive data readout from its Phase III TORCHLIGHT study.
Nectin Therapeutics, Merck Team Up on Immunotherapy Combo Trial in Solid Cancers
The Phase I trial is evaluating Nectin's investigational NTX1088 with Merck's PD-1 inhibitor Keytruda in advanced solid tumors expressing PVR.
Innovent Biologics, NeoCura Biomedical Technology Partner on Bespoke Immunotherapy Trial in China
The firms will evaluate whether NeoCura's personalized neoantigen cancer vaccine improves patients' ability to respond to Innovent's PD-1 inhibitor sintilimab.